<div class="data-content">

  <ul class="mxb-6 mlr-1">
    <li>
      Bakdach D, Elajez R, Bakdach AR, Awaisu A, De Pascale G, Ait Hssain A. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. J Clin Med. 2022;11(23):6898. Published 2022 Nov 22. doi:10.3390/jcm11236898
    </li>
    <li>
      Booke H, Friedrichson B, Draheim L, et al. No Sequestration of Commonly Used Anti-Infectives in the Extracorporeal Membrane Oxygenation (ECMO) Circuit-An Ex Vivo Study. Antibiotics (Basel). 2024;13(4):373. Published 2024 Apr 19. doi:10.3390/antibiotics13040373
    </li>
    <li>
      Cheng V, Abdul-Aziz MH, Burrows F, et al. Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). Clin Pharmacokinet. 2022;61(6):847-856. doi:10.1007/s40262-021-01106-x
    </li>
    <li>
      Ha MA, Sieg AC. Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation. Pharmacotherapy. 2017;37(2):221-235. doi:10.1002/phar.1882
    </li>
    <li>
      Hunt JP, McKnite AM, Green DJ, Whelan AJ, Imburgia CE, Watt KM. Interaction of ceftazidime and clindamycin with extracorporeal life support. J Infect Chemother. 2023;29(12):1119-1125. doi:10.1016/j.jiac.2023.08.007
    </li>
    <li>
      Kim M, Mahmood M, Estes LL, et al. A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation. Crit Care. 2024;28(1):326. Published 2024 Oct 4. doi:10.1186/s13054-024-05101-z
    </li>
    <li>
      Knox C, Wilson M, Klinger CM, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265-D1275. doi:10.1093/nar/gkad976
    </li>
    <li>
      Olney KB, Thomas JK, Johnson WM. Review of novel β-lactams and β-lactam/β-lactamase inhibitor combinations with implications for pediatric use. Pharmacotherapy. 2023;43(7):713-731. doi:10.1002/phar.2782
    </li>
    <li>
      Patel JS, Kooda K, Igneri LA. A Narrative Review of the Impact of Extracorporeal Membrane Oxygenation on the Pharmacokinetics and Pharmacodynamics of Critical Care Therapies. Ann Pharmacother. 2023;57(6):706-726. doi:10.1177/10600280221126438
    </li>
    <li>
      Shekar K, Roberts JA, Welch S, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol. 2012;12:29. Published 2012 Nov 28. doi:10.1186/1471-2253-12-29
    </li>
    <li>
      Yalcin N, Sürmelioğlu N, Allegaert K. Population pharmacokinetics in critically ill neonates and infants undergoing extracorporeal membrane oxygenation: a literature review. BMJ Paediatr Open. 2022;6(1):e001512. doi:10.1136/bmjpo-2022-001512
    </li>
    <li>
      Red Book 2021: Report of the committee on infectious diseases, edited by David W. Kimberlin, American Academy of Pediatrics, 2021.
    </li>
    <li>
      NeoFax/Pediatrics in Micromedex. Merative US LP, https://www.micromedexsolutions.com August 22, 2024.
    </li>
  </ul>
</div>